Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results

Haematologica. 2024 Oct 1;109(10):3357-3362. doi: 10.3324/haematol.2023.283992.
No abstract available

Publication types

  • Letter
  • Clinical Trial, Phase II

MeSH terms

  • Adult
  • Aged
  • Drug Resistance, Neoplasm
  • Female
  • Histone Deacetylase Inhibitors / administration & dosage
  • Histone Deacetylase Inhibitors / adverse effects
  • Histone Deacetylase Inhibitors / therapeutic use
  • Humans
  • Lymphoma, T-Cell, Peripheral* / drug therapy
  • Lymphoma, T-Cell, Peripheral* / mortality
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / pathology
  • Recurrence
  • Treatment Outcome

Substances

  • Histone Deacetylase Inhibitors